EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of Lemborexant‐Based Sleep Medication Formulary on Benzodiazepine Reduction and Clinical Outcomes: A Single‐Center Retrospective Study

Shunya Aoki iD, Katsutoshi Takada, Tatsuru Sugama, Mitsugi Kimiwada, Tatsuya Hoshino, Kaori Koike, Hirokazu Akada, Takahisa Saiga, Shigeki Sato, Ryosuke Shinkai, Yukihiro Shibata iD, Takashi Tomita

Neuropsychopharmacology Reports · 2025-09 · 45 (3)

DOI: 10.1002/npr2.70054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 08.09.2025. Verfasst von Shunya Aoki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Department, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan. Hauptthemen laut MEDLINE: Benzodiazepines, Hypnotics and Sedatives, Pyridines, Pyrimidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Benzodiazepine and non‐benzodiazepine hypnotics (Z‐drugs) are known risk factors for adverse events, including delirium and falls. Although formularies are intended to promote appropriate prescribing, few comprehensive studies have assessed their clinical impact in the context of sleep medications. This study aimed to evaluate changes in hypnotic prescribing patterns and associated clinical outcomes following the implementation of a sleep medication formulary. A psychiatric liaison team developed and implemented a formulary in April 2024, recommending lemborexant as the first‐line treatment and eszopiclone as the second‐line option. This single‐center, retrospective study compared patients admitted and discharged during the 12 months before (April 2023 to March 2024; n = 12 633) and after (April 2024 to March 2025; n = 12 931) implementation. Outcome measures included monthly prescription volumes, diazepam equivalents, use in clinical pathways and prescription sets, delirium incidence, nighttime falls, and length of hospital stay. Statistical analyses were performed using the Mann–Whitney U ‐test and Fisher's exact test. Following implementation, prescription volumes of lemborexant and eszopiclone increased significantly, whereas diazepam equivalents decreased from 10 682 mg to 4117 mg. All 104 clinical pathways and prescription sets previously using benzodiazepine hypnotics or Z‐drugs were converted to lemborexant. Monthly delirium cases declined from 12.5 to 8.0, and the proportion of nighttime falls among patients receiving benzodiazepine hypnotics or Z‐drugs decreased from 24.0% to 11.5%. The median hospital stay also decreased from 8 to 7 days. These findings suggest that formulary implementation effectively optimized hypnotic prescribing and contributed to improved clinical outcomes and patient safety in an acute care setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzodiazepinesHypnotics and SedativesPyridinesPyrimidinesPractice Patterns, Physicians'HumansRetrospective StudiesMaleFemaleMiddle AgedAgedEszopicloneDeliriumAdultAccidental FallsSleep Initiation and Maintenance DisordersLength of StayAged, 80 and over

Stichwörter der Autor:innen

accidental fallsdeliriumformularyhypnotics and sedativeslemborexant

Substanzen

BenzodiazepinesHypnotics and SedativesPyridineslemborexantPyrimidinesEszopiclone

Autor:innen und Institutionen

  • Pharmaceutical Department, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan.
  • Nursing Department, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan.
  • Department of Psychiatry, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan.
  • Department of Pharmaceutical Sciences, School of Pharmacy at Narita International University of Health and Welfare, Narita, Chiba, Japan.
  • Department of Pharmacy, International University of Health and Welfare Mita Hospital, Minato-ku, Tokyo, Japan.

ORCID-Profile: Shunya Aoki, Yukihiro Shibata

Zitieren

APA

Aoki, S., Takada, K., Sugama, T., Kimiwada, M., Hoshino, T., Koike, K., Akada, H., Saiga, T., Sato, S., Shinkai, R., Shibata, Y., & Tomita, T. (2025). Effect of Lemborexant‐Based Sleep Medication Formulary on Benzodiazepine Reduction and Clinical Outcomes: A Single‐Center Retrospective Study. Neuropsychopharmacology Reports, 45(3). https://doi.org/10.1002/npr2.70054

Vancouver

Aoki S, Takada K, Sugama T, Kimiwada M, Hoshino T, Koike K, et al. Effect of Lemborexant‐Based Sleep Medication Formulary on Benzodiazepine Reduction and Clinical Outcomes: A Single‐Center Retrospective Study. Neuropsychopharmacology Reports. 2025;45(3). doi:10.1002/npr2.70054

BibTeX
@article{Aoki2025,
  author = {Aoki, Shunya and Takada, Katsutoshi and Sugama, Tatsuru and Kimiwada, Mitsugi and Hoshino, Tatsuya and Koike, Kaori and Akada, Hirokazu and Saiga, Takahisa and Sato, Shigeki and Shinkai, Ryosuke and Shibata, Yukihiro and Tomita, Takashi},
  title = {Effect of Lemborexant‐Based Sleep Medication Formulary on Benzodiazepine Reduction and Clinical Outcomes: A Single‐Center Retrospective Study},
  journal = {Neuropsychopharmacology Reports},
  year = {2025},
  volume = {45},
  number = {3},
  doi = {10.1002/npr2.70054}
}
Kostenlos starten →